5-氟尿嘧啶联合丝裂霉素C与5-氟尿嘧啶联合甲基环己亚硝脲治疗晚期结肠癌：西南肿瘤协作组研究

5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.

作者信息

Buroker T, Kim P N, Groppe C, McCracken J, O'Bryan R, Panettiere F, Coltman C, Bottomley R, Wilson H, Bonnet J, Thigpen T, Vaitkevicius V K, Hoogstraten B, Heilbrun L

出版信息

Cancer. 1978 Sep;42(3):1228-33. doi: 10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co;2-s.

DOI:10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co;2-s

PMID:359121

Abstract

The Southwest Oncology Group (SWOG) in a randomized trial evaluated 5FU infusions in combination with either Mitomycin-C or Methyl-CCNU in patients with disseminated large bowel cancer. A response rate of 18% was noted on the 5FU-Mitomycin limb as compared to 16% on the Methyl-CCNU arm (p = .39). Median survival for all treated patients was 43 weeks on both arms. Myelosuppression was found to be more significant on the Mitomycin-C arm. Regression analysis demonstrated that performance status, sex, and primary site were significant pretreatment characteristics for predicting survival. The response rates associated with this burdensome method of 5FU administration in combination with either Mitomycin-C or Methyl-CCNU appear to offer little advantage over bolus 5FU alone.

摘要

西南肿瘤协作组（SWOG）在一项随机试验中，评估了5-氟尿嘧啶（5FU）输注联合丝裂霉素-C或甲基环己亚硝脲用于播散性大肠癌患者的疗效。5FU-丝裂霉素组的缓解率为18%，而甲基环己亚硝脲组为16%（p = 0.39）。两组所有接受治疗患者的中位生存期均为43周。发现丝裂霉素-C组的骨髓抑制更为显著。回归分析表明，体能状态、性别和原发部位是预测生存的重要预处理特征。5FU这种繁琐给药方法联合丝裂霉素-C或甲基环己亚硝脲，与单独使用5FU推注相比，似乎没有什么优势。